← Browse by Condition
Medical Condition

ductal breast carcinoma in situ

Total Trials
2
Recruiting Now
2
Trial Phases
Various

ClinicalMetric tracks all active clinical trials for ductal breast carcinoma in situ sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — ductal breast carcinoma in situ Clinical Trials

How many clinical trials are currently recruiting for ductal breast carcinoma in situ?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for ductal breast carcinoma in situ, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for ductal breast carcinoma in situ?
ductal breast carcinoma in situ research spans multiple clinical trial phases. Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a ductal breast carcinoma in situ clinical trial?
Eligibility criteria for ductal breast carcinoma in situ trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
PreludeDx 1 trial
M.D. Anderson Cancer Center 1 trial

Recruiting Clinical Trials

NCT03448926
Recruiting

The PREDICT Registry:

Enrollment
3,000 pts
Location
United States
Sponsor
PreludeDx
View Trial →
NCT02918474
Recruiting

Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Enrollment
15 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology